Navigation Links
Once-Daily Combo Works for New HIV Patients

Tazanavir/ritonavir as good as twice-daily dose of lopinavir/ritonavir, study says

FRIDAY, Aug. 1 (HealthDay News) -- Once-daily treatment with tazanavir/ritonavir (A/R) is as effective as twice-daily treatment with lopinavir/ritonavir (L/R) in HIV patients who are starting antiretroviral treatment for the first time, a European study shows.

Based on their findings, the researchers recommended once-daily A/R as a first-line treatment option for treatment-naive HIV patients since it has a number of advantages over the currently recommended twice-daily L/R.

The study included 883 treatment-naive HIV patients who were randomly assigned to receive A/R 300/100 milligrams once daily (440 patients) or L/R 400/100 milligrams twice daily (443 patients). Both regimens were in combination with tenofovir/emtricitabine 300/200 once daily, as is standard.

After 48 weeks of treatment, 78 percent of patients receiving A/R and 76 percent of those receiving L/R had a viral load of less than 50 copies per milliliters in their blood, and both groups showed similar increases in the numbers of immune system CD4 cells. Six percent of patients in both groups failed on the treatments, and two patients in the A/R group developed resistance mutations to treatment, compared with none in the L/R group.

Serious side effects were reported in 12 percent of the A/R patients and 10 percent of the L/R patients, but fewer A/R patients experienced treatment-related diarrhea (2 percent vs. 11 percent) and nausea (4 percent vs. 8 percent). None of the L/R patients developed jaundice, which occurred in 4 percent of A/R patients.

"In treatment-naive patients, atazanavir/ritonavir once-daily demonstrated similar antiviral efficacy to lopinavir/ritonavir twice daily, with less gastrointestinal toxicity but with a higher rate of hyperbilirubinaemia...the results of this study support the use of once-daily atazanavir/ritonavir as a recommended first-line treatment option, with a number of patient benefits over the currently recommended ritonavir-boosted twice-daily lopinavir for the treatment of HIV-infected antiretroviral-naive patients," the researchers concluded.

The study appears online in The Lancet, and was expected to be published in an upcoming print edition of the journal.

More information

The American Academy of Family Physicians has more about HIV medicines.

-- Robert Preidt

SOURCE: The Lancet, news release, Aug. 2, 2008

Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Labopharms Once-Daily Tramadol Product Launched in South Korea, Australia, Romania and Austria
2. New Data Highlights Positive Results of Namenda (Memantine HCl) Once-Daily Extended-Release Formulation
3. FDA accepts Labopharms response for once-daily tramadol as complete Class 2 response
4. Labopharm Reaquires UK Sales And Marketing Rights to Its Once-Daily Tramadol Product
5. Labopharm Submits Complete Response to FDA as a Result of Outcome of Appeal Process for Once-Daily Tramadol
6. Labopharm Receives Response from FDA Regarding its Once-Daily Tramadol Product
7. FDA approves VYVANSE, first and only once-daily prodrug stimulant to treat ADHD in adults
8. Labopharm Appeals FDAs Decision on Once-Daily Tramadol to Next Supervisory Level After Additional Analysis Supports Efficacy
9. Once-Daily Insulin Shot Proves Effective in Study
10. A Once-Daily Oral Drug for Chronic Obstructive Pulmonary Disease That Treats COPD-Related Inflammation Could Achieve Blockbuster Status
11. Labopharms Once-Daily Tramadol Approved in South Korea and Australia
Post Your Comments:
(Date:6/26/2016)... ... ... blind and certified personal trainer is helping to develop a weight loss fitness plan that ... the two major problems leading the fitness industry today:, , All ... They don’t eliminate all the reasons people quit their exercise program , ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due ... up a new, often overlooked aspect of head lice: the parasite’s ability to live away ... a common occurrence, but a necessary one in the event that lice have simply gotten ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 26, 2016 ... care operating models within the health care industry is ... financial efficiency , Deloitte offers a suite of ... business issues impacting efficient cost optimization: labor resource analysis, ... These services facilitate better outcomes and better economics ...
(Date:6/24/2016)... Dublin ... of the " Global Markets for Spectroscopy Equipment" ... This report focuses on the global ... including its applications in various applications. The report deals ... three main industries: pharmaceutical and biotechnology, food and beverage, ...
(Date:6/24/2016)... June 24, 2016 Research and Markets ... for Companion Diagnostic Tests" report to their offering. ... Companion Diagnostics The World Market for Companion ... medicine diagnostics. Market analysis in the report includes the following: ... (In Vitro Diagnostic Kits) by Region (N. America, EU, ROW), ...
Breaking Medicine Technology: